SLC5A2 and type 2 diabetes mellitus: Current T2DM treatments, such as SGLT2 inhibitors and GLP-1 agonists have been associated with cardiac benefit, which may be related to buffering ER stress [23,87,88], suggesting that related mechanisms, such as upstream endogenous lipid regulators of SGLT-2 or GLP-1, might also offer new potential to understand, treat, and slow the progression of T2DM complications.